Open AccessAnaemia and iron deficiency in chronic heart failure patients
Author(s) -
Н. Т. Ватутин,
Г. Г. Тарадин,
И. В. Канишева,
V. V. Venzheha
Publication year - 2019
Publication title -
kardiologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.159
H-Index - 16
eISSN - 2412-5660
pISSN - 0022-9040
DOI - 10.18087/cardio.2638
Subject(s) - anemia , transferrin saturation , medicine , erythropoietin , iron deficiency , transferrin , ferritin , serum iron , bone marrow , heart failure , intensive care medicine , haematopoiesis , hemodynamics , gold standard (test) , erythropoiesis , cardiology , biology , genetics , stem cell
Tis review focused on prevalence of anemia and iron defciency (ID) in CHF and their eect on the course and prognosis of this condition. Based on evaluation of numerous laboratory data defnitions of anemia and ID were suggested. Specifcally, a diagnostic value of measuring serum iron, serum ferritin, transferrin saturation, total iron-binding capacity, and concentration of soluble transferrin receptors was discussed. Te review highlighted the importance of measuring bone marrow iron, which is rarely used in everyday clinical practice even though this test is considered a «gold standard» of ID diagnosis. Te review provided an insight into pathogenetic mechanisms of ID in CHF including insufcient iron supply, role of inammation, erythropoietin, RAS, and eects of some pharmacological therapies. Te authors described physiological consequences of ID and anemia, activation of hemodynamic and non-hemodynamic compensatory mechanisms, which develop in response to anemia and not infrequently aggravate CHF. Special atention was paid to current approaches to treatment of anemia and ID in CHF, including a discussion of efcacy and safety of oral and intravenous dosage forms of iron and hemopoiesis stimulators.